Article

Regenera buys Advanced Ocular Systems

Marblehead, MA—A Western Australia-based drug developer will acquire Advanced Ocular Systems (AOS) in a $31 million all-stock deal.

Marblehead, MA-A Western Australia-based drug developer will acquire Advanced Ocular Systems (AOS) in a $31 million all-stock deal.

AOS, which will own 45% of Regenera, is led by Ken Taylor, OD, its president and chief executive officer, and a frequent consultant to ophthalmic companies. Founded in early 2005, AOS develops and commercializes devices to treat refractive disorders such as presbyopia.

The merger creates a new global ophthalmic company with a strong pipeline of refractive and retinal technology and products and emerging revenues from existing licensed products, the companies said. The new company will be based in Marblehead, MA, with research and development and administrative operations in Australia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
© 2025 MJH Life Sciences

All rights reserved.